Insider Activity Highlights the Momentum Behind Cosmos Health’s Contract‑Manufacturing Push On May 19, 2026, owner Theodoros Christos Karkantzos received a sizable grant of 20 000 shares under the 2024‑2025 Omnibus Incentive Plan, reflecting a direct buy of common stock at $0.28 per share. The same day he also sold 35 000 restricted stock units, a routine vesting event that does not affect cash flow. The transaction, exempt under Rule 16b‑3, signals that the company’s leadership remains confident that the stock price will rise as new manufacturing contracts come to life.
What the Numbers Mean for Investors Karkantzos’s holdings grew from 15 000 to 35 000 shares—an increase that, while modest in absolute terms, represents a 133 % jump in his stake. The buy is priced at $0.28, only 10 % above the close price of $0.21 on the filing date, suggesting a willingness to invest even as the company’s share price remains under pressure. For shareholders, this insider confidence can serve as a contrarian cue: insiders are buying when the market is bearish, possibly betting on the momentum from the two new contract‑manufacturing agreements announced earlier in the year.
Karkantzos’s Trading Footprint Historically, Karkantzos has been a passive investor. His only other disclosed transaction was a 15 000‑share purchase on December 31, 2025, when the stock traded at $0.00 in the filing but was actually around $0.25 on the market. This pattern—periodic purchases tied to incentive plans—suggests that he is more of a long‑term holder than a speculative trader. The recent award aligns with the company’s strategic pivot to high‑margin contract manufacturing, reinforcing the idea that insiders are aligning their personal wealth with the company’s growth engine.
Company‑Wide Insider Dynamics Other insiders, including CEO Grigorios Siokas and CFO Georgios Terzis, have made sizeable purchases—Siokas bought over 12 million shares on May 19, 2026, and Terzis added more than 2 million shares the same day. These coordinated buying sprees are a classic signal of insider conviction, especially when paired with the company’s aggressive contract strategy. While the overall market cap remains modest at $12.5 million and the stock has slipped 54 % year‑to‑date, the insider activity suggests a belief that the company’s new manufacturing pipeline will lift valuation over the next 12 months.
Bottom Line for the Investment Community The insider buying, coupled with a 1,694 % surge in social‑media buzz, indicates that investor attention is heating up. For those considering a position, the key questions are: Will the contract‑manufacturing revenue streams materialize quickly enough to justify a turnaround? And can the stock’s current valuation accommodate the upside implied by the insiders’ confidence? If Cosmos Health can close the new contracts and deliver incremental margins, the insider purchases may presage a rebound that could unlock value for both long‑term holders and opportunistic traders alike.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-05-19-05:00 | Karkantzos Theodoros Christos () | Buy | 20,000.00 | 0.28 | Common Stock, par value $.001 |
| 2026-05-19-05:00 | Karkantzos Theodoros Christos () | Sell | 35,000.00 | N/A | Restricted Stock Unit |
| 2026-05-19-05:00 | Demetriades Demetrios G. (Secretary) | Buy | 20,000.00 | 0.28 | Common Stock, par value $.001 |
| 2026-05-19-05:00 | Demetriades Demetrios G. (Secretary) | Sell | 20,000.00 | N/A | Restricted Stock Unit |
| 2026-05-19-05:00 | Hoidas John James () | Buy | 20,000.00 | 0.28 | Common Stock, par value $.001 |
| 2026-05-19-05:00 | Hoidas John James () | Sell | 20,000.00 | N/A | Restricted Stock Unit |
| 2026-05-19-05:00 | Bhutawala Suhel () | Buy | 20,000.00 | 0.28 | Common Stock, par value $.001 |
| 2026-05-19-05:00 | Bhutawala Suhel () | Sell | 20,000.00 | N/A | Restricted Stock Unit |
| 2026-05-19-05:00 | Aslidis Anastasios () | Buy | 40,000.00 | 0.28 | Common Stock, par value $.001 |
| 2026-05-19-05:00 | Aslidis Anastasios () | Sell | 40,000.00 | N/A | Restricted Stock Unit |
| 2026-05-19-05:00 | Terzis Georgios (Chief Financial Officer) | Buy | 850,000.00 | 0.28 | Common Stock, par value $.001 |
| 2026-05-19-05:00 | Terzis Georgios (Chief Financial Officer) | Sell | 850,000.00 | N/A | Restricted Stock Unit |
| 2026-05-19-05:00 | Siokas Grigorios (Chief Executive Officer) | Buy | 2,350,000.00 | 0.28 | Common Stock, par value $.001 |
| 2026-05-19-05:00 | Siokas Grigorios (Chief Executive Officer) | Sell | 2,350,000.00 | N/A | Restricted Stock Unit |
| 2025-12-31-05:00 | Siokas Grigorios (Chief Executive Officer) | Buy | 1,350,000.00 | 0.00 | Common Stock, par value $.001 |
| 2025-12-31-05:00 | Siokas Grigorios (Chief Executive Officer) | Buy | 100,000.00 | 0.00 | Common Stock, par value $.001 |
| 2025-12-31-05:00 | Aslidis Anastasios () | Buy | 20,000.00 | 0.00 | Common Stock, par value $.001 |
| 2025-12-31-05:00 | Terzis Georgios (Chief Financial Officer) | Buy | 490,000.00 | 0.00 | Common Stock, par value $.001 |
| 2025-12-31-05:00 | Demetriades Demetrios G. (Secretary) | Buy | 15,000.00 | 0.00 | Common Stock, par value $.001 |
| 2025-12-31-05:00 | Hoidas John James () | Buy | 15,000.00 | 0.00 | Common Stock, par value $.001 |
| 2025-12-31-05:00 | Karkantzos Theodoros Christos () | Buy | 15,000.00 | 0.00 | Common Stock, par value $.001 |
| 2025-12-31-05:00 | Bhutawala Suhel () | Buy | 15,000.00 | 0.00 | Common Stock, par value $.001 |
